These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4028029)

  • 1. Humoral immune response of patients receiving specific active immunotherapy for renal cell carcinoma.
    Miller GA; Pontes JE; Huben RP; Goldrosen MH
    Cancer Res; 1985 Sep; 45(9):4478-82. PubMed ID: 4028029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
    Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
    Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
    Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
    Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma.
    Brouwenstijn N; Hoogstraten C; Verdegaal EM; Van der Spek CW; Deckers JG; Mulder A; Osanto S; Schrier PI
    J Immunother; 1998 Nov; 21(6):427-34. PubMed ID: 9807737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
    Kurokawa T; Oelke M; Mackensen A
    Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses.
    Zorn U; Duensing S; Langkopf F; Anastassiou G; Kirchner H; Hadam M; Knüver-Hopf J; Atzpodien J
    Cancer Biother Radiopharm; 1997 Jun; 12(3):157-65. PubMed ID: 10851462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.
    Faiena I; Comin-Anduix B; Berent-Maoz B; Bot A; Zomorodian N; Sachdeva A; Said J; Cheung-Lau G; Pang J; Macabali M; Chodon T; Wang X; Cabrera P; Kaplan-Lefko P; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
    J Immunother; 2020; 43(9):273-282. PubMed ID: 32925563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.
    Antonia SJ; Seigne JD
    World J Urol; 2000 Apr; 18(2):157-63. PubMed ID: 10854153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
    Sievers E; Albers P; Schmidt-Wolf IG; Märten A
    J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
    Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
    J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
    Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
    J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
    Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
    Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
    Höltl L; Zelle-Rieser C; Gander H; Papesh C; Ramoner R; Bartsch G; Rogatsch H; Barsoum AL; Coggin JH; Thurnher M
    Clin Cancer Res; 2002 Nov; 8(11):3369-76. PubMed ID: 12429623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.
    Seliger B; Menig M; Lichtenfels R; Atkins D; Bukur J; Halder TM; Kersten M; Harder A; Ackermann A; Beck J; Muehlenweg B; Brenner W; Melchior S; Kellner R; Lottspeich F
    Proteomics; 2003 Jun; 3(6):979-90. PubMed ID: 12833523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
    Tani K; Azuma M; Nakazaki Y; Oyaizu N; Hase H; Ohata J; Takahashi K; OiwaMonna M; Hanazawa K; Wakumoto Y; Kawai K; Noguchi M; Soda Y; Kunisaki R; Watari K; Takahashi S; Machida U; Satoh N; Tojo A; Maekawa T; Eriguchi M; Tomikawa S; Tahara H; Inoue Y; Yoshikawa H; Yamada Y; Iwamoto A; Hamada H; Yamashita N; Okumura K; Kakizoe T; Akaza H; Fujime M; Clift S; Ando D; Mulligan R; Asano S
    Mol Ther; 2004 Oct; 10(4):799-816. PubMed ID: 15451464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.